Zevra Therapeutics
Zevra Therapeutics, a biopharmaceutical firm, innovates safer therapies for pain, ADHD, and CNS diseases using its proprietary LAT approach.
Founded
2006Zevra Therapeutics, a biopharmaceutical firm, innovates safer therapies for pain, ADHD, and CNS diseases using its proprietary LAT approach.
Zevra Therapeutics, founded to innovate in the biopharmaceutical sector, focuses on developing safer therapies for pain, ADHD, and central nervous system (CNS) diseases. Utilizing its proprietary Ligand Activated Therapy (LAT) approach, Zevra aims to create abuse-resistant opioid pain relievers and improve existing drugs to expedite development timelines. Their product portfolio includes Olpruva® and Azstarys®, targeting specific medical needs within their market focus.
Notable figures affiliated with Zevra include its leadership team and board of directors, who bring extensive industry experience. The company has achieved significant milestones, such as the acquisition of Acer Therapeutics, expanding its therapeutic reach. Zevra's impact is marked by its commitment to addressing unmet medical needs through innovative drug development, contributing to advancements in pain management and CNS disease treatment.
Companies similar to Zevra Therapeutics include Latigo Biotherapeutics, Trevena, Zena Therapeutics and Azevan Pharmaceuticals.
Zevra Therapeutics was founded in 2006.
Zevra Therapeutics' headquarters is located in Orlando, FL, US.
Zevra Therapeutics' most recent funding round was for $78M (USD) in December 2019.
As of Dec 1, 2019, Zevra Therapeutics has disclosed funding of $153.8M (USD). Undisclosed round amounts are excluded.
Zevra Therapeutics has 40 employees as of Feb 5, 2024.
Azevan Pharmaceuticals
azevan.com
